Network Version
NVP-BHG712 Data Sheet
| Product Name: | NVP-BHG712 |
 |
|---|---|---|
| CAS No.: | 940310-85-0 | |
| Cat. No.: | HY-13258A | |
| MWt: | 503.48 | |
| Formula: | C26H20F3N7O | |
| Purity : | >98% | |
| Solubility: | 10 mM in DMSO | |
| Mechanisms: | Target: Cancer | |
| Biological Activity: | ||
| NVP-BHG712 is an oral active EphB4 kinase autophosphorylation inhibitor, with IC50 values of 3.3 nM and 3.0 nM for EphA2 and EphB4, respectively[1][2]. IC50 & Target: IC50: 3.3 nM (EphA2), 3 nM (EphB4)[2]. In Vitro: NVP-BHG712 inhibits VEGF driven vessel formation, while it has only little effects on VEGF receptor (VEGFR) activity. The data suggests a close cross talk between the VEGFR and EphR signaling during vessel formation[2]. In Vivo: NVP-BHG712 (3, 10 and 30 mg/kg, p.o., daily) inhibits VEGF driven tissue growth and angiogenesis[2]. | ||
1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA
Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Web:www.medchemexpress.com